Taisho Pharma Co
Taisho Pharmaceutical Co., Ltd., commonly referred to as Taisho Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1912, the company has a rich history of innovation and growth, with significant operations across Asia and beyond. Taisho Pharma focuses on a diverse range of sectors, including over-the-counter (OTC) medications, prescription drugs, and health supplements. Its core products, such as pain relief and digestive aids, are distinguished by their commitment to quality and efficacy. With a strong market position, Taisho Pharma has achieved notable milestones, including strategic partnerships and expansions that enhance its global footprint. The company continues to be recognised for its contributions to healthcare, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Taisho Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taisho Pharma Co's score of 29 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Taisho Pharma Co's reported carbon emissions
In 2021, Taisho Pharma Co., headquartered in Japan, reported total carbon emissions of approximately 50,085,000 kg CO2e. This figure includes Scope 1 emissions of about 22,353,000 kg CO2e and Scope 2 emissions of around 27,732,000 kg CO2e. The company also disclosed significant Scope 3 emissions, with capital goods contributing approximately 47,764,000 kg CO2e and purchased goods and services accounting for about 81,264,000 kg CO2e. Taisho Pharma has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 46% by the fiscal year ending March 31, 2031, compared to the fiscal year ended March 31, 2014. Additionally, the company has pledged to achieve a 100% reduction in its Net Scope 1 and Scope 2 emissions by 2030. These targets reflect a long-term commitment to sustainability and align with industry standards for climate action. The emissions data is not cascaded from any parent organization, indicating that Taisho Pharma is independently reporting its carbon footprint and climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Scope 1 | 26,236,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 30,028,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taisho Pharma Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
